Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports positive lung cancer data for Alecensa

Roche reports positive lung cancer data for Alecensa

10th April 2017

Roche has announced new clinical trial data demonstrating the benefits of its drug Alecensa in the treatment of non-small cell lung cancer (NSCLC).

Results from the phase III ALEX study showed that Alecensa, when used as a first-line treatment, significantly improved progression-free survival rates compared to an established therapy in people with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC.

This meant the drug was able to meet its primary efficacy endpoint, and represented the second phase III trial to show that Alecensa was superior as an initial treatment in this type of lung cancer compared to existing options.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "We hope to bring Alecensa as an initial treatment for people with ALK-positive NSCLC as soon as possible, and will discuss this data with global health authorities."

Alecensa was granted conditional European marketing authorisation in February for use as a monotherapy among people with ALK-positive NSCLC previously treated with crizotinib. The ALEX study acts as a post-authorisation safety trial, allowing Roche to meet the obligation necessary to convert this conditional approval into a full ratification.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801834521-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.